Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Everest Medicines Limited operates as a biopharmaceutical firm, concentrating its efforts on bringing innovative treatments to market. The company handles the entire process, from identifying and acquiring promising drug candidates to developing them through clinical trials and ultimately commercializing them. Its core objective is to address significant gaps in existing medical treatments within the broader Asia Pacific region, with a particular focus on Greater China. The company boasts a strong portfolio, including eleven experimental drug candidates currently undergoing clinical evaluation. These investigational therapies are designed to combat a range of serious conditions, including various forms of cancer (oncology), immune system disorders (immunology), heart and kidney ailments (cardio-renal), and infectious diseases. Everest Medicines Limited was founded in 2017 and is based in Shanghai, China.
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E.
Target Price
The average target price of 1952.HK is 48.6 and suggests 76.7% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to i